Cerebral Therapeutics, Inc.

Cerebral Therapeutics, Inc.

is a clinical-stage biopharmaceutical company based in Aurora, Colorado, focused on developing innovative therapies for refractory neurological diseases, particularly severe refractory epilepsy. Founded in 2010, the company aims to address chronic neurological conditions that lack effective treatments by delivering medications directly to the central nervous system, bypassing the blood-brain barrier. The company's core technology, ICVRxTM, enables the intracerebroventricular delivery of therapeutics directly into the brain's ventricles. Its product portfolio includes specialized formulations of reformulated off-patent drugs, biologics, oligonucleotides, antibodies, and enzymes, all delivered through implanted drug-device systems. The lead investigational product, CT-010, is currently in clinical trials for treating refractory epilepsy. Cerebral Therapeutics primarily serves the healthcare industry, targeting patients with severe refractory epilepsy and other uncontrolled neurological diseases.